

图 商 银 行 全 资 附 属 机 杠 A Wholly Owned Subsidiary Of China Merchants Bank

Meituan Dianping (3690 HK)

Faster recovery ahead with expanding TAM

Meituan Dianping ("**MD**") delivered upbeat 1Q20 results, with revenue 7% above consensus, and net loss largely below consensus. Given its better-than-expected recovery pace and above-peer performance, we turn more bullish on its 2Q20E outlook and secular growth. We raised its revenue by 2%/3%/6%, and adj. net profit by 69%/8%/6% in FY20/21/21E, with higher TP of HK\$147 (from HK\$120).

- 1Q20 all-round beat. 1Q20 revenue dropped 12.6% YoY, 7%/7% above consensus/our estimate. Adj. net loss reached —RMB216mn, largely better than consensus of -RMB1.1bn, mainly on lower S&M and narrowing loss of initiatives. By segment, revenue of food delivery/ in-store, hotel and travel/ new initiatives -11%/-31%/+5% YoY (vs. our estimate of -13%/-35%/+0% YoY). OPM of food delivery/ in-store, hotel and travel/ new initiatives came in at -1%/+22%/-33% in 1Q20, better than our estimate of -3%/+20%/-40%.We are impressed by this eye-catching results with upbeat margin and better-than-feared growth of all segments.
- Faster recovery with better outlook. Despite short-term challenges from epidemic, MD performed more resilient than market expectation and peers. Food delivery GTV -5% YoY (vs. our estimate of -7% YoY), orders -17% YoY, with take rate at 13.3% (vs. 14% in 4Q19). AOV +14.4% YoY in 1Q20, a positive signal for users' rising demand. Supply side had recovered to 100% of pre-epidemic level, with higher mix of brand merchants. We expect food delivery GTV to achieve positive YoY growth from 2Q20E, and benefit from COVID-19, in terms of user adoption and merchant expansion. In-store, hotel and travel segment would still decline YoY in 2Q20E, in which hotel to see slower recovery with both decreasing room nights and ADR. Mgmt stated that competition was more moderate in the epidemic, thus hotel OPM would perform better than FY19. MD would step up its investment in new initiatives, to seize structural opportunities.
- Maintain BUY. Given its strong 1Q20 results, we turn more bullish on MD's recovery pace and secular growth with margin improvement. We raised its revenue by 2%/3%/6%, and adjusted its bottom line by 69%/8%/6% in FY20/21/21E. Our new SOTP-based TP is HK\$147 (implying 5.0x FY21E P/S, or 54x FY21E P/E). We see high visibility for MD to long-term benefit from structural changes in this epidemic, including online consumption tailwinds, grocery business and digital operation.

Earnings Summary

Larinings Summary					
(YE 31 Dec)	FY18A	FY19A	FY20E	FY21E	FY22E
Revenue (RMB mn)	65,227	97,529	110,112	162,567	207,567
YoY growth (%)	92	50	13	48	28
Net income (RMB mn)	(8,517)	4,657	2,153	15,180	23,691
EPS (RMB)	(3.13)	0.79	0.35	2.42	3.67
YoY growth (%)	NA	NA	(55)	585	52
Consensus (RMB)	NA	NA	0.51	2.47	3.83
P/E (x)	NA	144	319	47	31
P/S (x)	10.1	6.7	6.0	4.0	3.2
Yield (%)	0.0	0.0	0.0	0.0	0.0
ROE (%)	(133.5)	3.7	(1.9)	10.0	16.0
Net gearing (%)	Net cash				

PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE

Source: Company data, Bloomberg, CMBIS estimates

BUY (Maintain)

Target Price HK\$147.0 (Previous TP HK\$120.0) Up/Downside +16.9% Current Price HK\$125.8

China Internet Sector

Sophie Huang (852) 3900 0889 sophiehuang@cmbi.com.hk

Stock Data

Mkt Cap (HK\$ mn)	733,023
Avg 3 mths t/o (HK\$ mn)	2809.2
52w High/Low (HK\$)	131/57
Total Issued Shares (mn)	5,081
Source: Bloomberg	

Shareholding Structure

Tencent	20.7%
Sequoia Capital	8.4%
Baillie Gifford	5.1%

Source: Bloomberg

Share Performance

	Absolute	Relative
1-mth	19.5%	24.2%
3-mth	17.9%	37.9%
6-mth	20.9%	40.2%

Source: Bloomberg

12-mth Price Performance



Source: Bloomberg

Auditor: PwC

Related Reports

- 1. Looking beyond 1H20E 31 Mar 2020
 - One-stop lifestyle shop at your fingertip
 28 Feb 2020

MORE REPORTS FROM BLOOMBERG: CMBR OR http://www.cmbi.com.hk



Figure 1: Earnings revision

		New			Old			Diff (%)	
RMB mn, Dec-YE	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E
Revenue	110,112	162,567	207,567	107,841	157,310	195,165	2.1%	3.3%	6.4%
Gross Profit	34,181	62,184	81,961	32,635	59,414	77,157	4.7%	4.7%	6.2%
Operating Profit	(1,039)	11,732	21,511	(1,858)	10,593	20,318	-44.1%	10.8%	5.9%
Net profit	2,153	15,180	23,691	1,277	14,012	22,383	68.6%	8.3%	5.8%
EPS (RMB)	0.35	2.42	3.67	0.21	2.24	3.47	68.6%	8.3%	5.8%
Gross Margin	31.0%	38.3%	39.5%	30.3%	37.8%	39.5%	+0.8ppts	+0.5ppts	+0.0ppts
Operating Margin	-0.9%	7.2%	10.4%	-1.7%	6.7%	10.4%	+0.8ppts	+0.5ppts	+0.0ppts
Net Margin	2.0%	9.3%	11.4%	1.2%	8.9%	11.5%	+0.8ppts	+0.4ppts	-0.1ppts

Source: Company data, CMBIS estimates

Figure 2: CMBIS estimates vs consensus

		CMBIS			Consensus			Diff (%)	
RMB mn, Dec-YE	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E
Revenue	110,112	162,567	207,567	111,698	157,775	198,381	-1.4%	3.0%	4.6%
Gross Profit	34,181	62,184	81,961	36,424	58,381	75,935	-6.2%	6.5%	7.9%
Operating Profit	(1,039)	11,732	21,511	1,404	14,525	24,932	-174.0%	-19.2%	-13.7%
Net profit	2,153	15,180	23,691	3,313	14,971	24,612	-35.0%	1.4%	-3.7%
EPS (RMB)	0.35	2.42	3.67	0.51	2.47	3.83	-30.2%	-2.1%	-4.0%
Gross Margin	31.0%	38.3%	39.5%	32.6%	37.0%	38.3%	-1.6ppt	+1.2ppts	+1.2ppts
Operating Margin	-0.9%	7.2%	10.4%	1.3%	9.2%	12.6%	-2.2ppts	-2.0ppts	-2.2ppts
Net Margin	2.0%	9.3%	11.4%	3.0%	9.5%	12.4%	-1.0ppts	-0.2ppts	-1.0ppts

Source: Company data, Bloomberg, CMBIS estimates

Figure 3: MD's 1Q20 Review

RMB mn	4Q18	1Q19	2Q19	3Q19	4Q19	1Q20	QoQ	YoY	Consensus	Diff %	CMBI	Diff %
Revenue	19,803	19,174	22,703	27,494	28,158	16,754	-40.5%	-12.6%	15,589	7%	16,204	7%
Operating profit	(3,735)	(1,304)	1,113	1,447	1,424	(1,716)	NA	NA	(1,419)	NA	(1,681)	NA
Net profit	(3,425)	(1,432)	877	1,335	1,458	(1,579)	NA	NA	(1,789)	NA	(1,659)	NA
Adj. net profit	(1,582)	(1,039)	1,494	1,942	2,270	(216)	NA	NA	(1,111)	NA	(1,166)	NA
Margin (%)												
Gross margin	34.5%	24.3%	28.6%	33.2%	31.2%	31.0%			24.5%			
Operating margin	-18.9%	-6.8%	4.9%	5.3%	5.1%	-10.2%			-9.1%			
Adj. net margin	-8.0%	-5.4%	6.6%	7.1%	8.1%	-1.3%			-7.1%			
Growth (%)												
Revenue (YoY)	89.0%	70.1%	50.6%	44.1%	42.2%	-12.6%			-18.7%			
Revenue (QoQ)	3.8%	-3.2%	18.4%	21.1%	2.4%	-40.5%			-44.6%			
Operating profit	NA	NA	NA	NA	NA	NA			NA			
Adj. net profit	NA	NA	NA	NA	NA	NA			NA			

Source: Company data, Bloomberg, CMBIS estimates

Figure 4: 1Q20 Revenue breakdown

	4Q18	1Q19	2Q19	3Q19	4Q19	1Q20	QoQ	YoY
Revenue (RMB mn)	19,803	19,174	22,703	27,494	28,158	16,754	-40.5%	-12.6%
Food Delivery	11,006	10,706	12,845	15,577	15,716	9,490	-39.6%	-11.4%
In-Store, Hotel, Travel	4,594	4,492	5,245	6,181	6,357	3,095	-51.3%	-31.1%
New Initiatives & Others	4,203	3,976	4,613	5,736	6,086	4,168	-31.5%	4.9%

Source: Company data



Figure 5: SOTP valuation

. igaio oi oo ii talaalioii						
Business (US\$ bn)	'21E Re v	OP Margin	'21E EBIT M	lethodology	Multiple	Value
Food Delivery	13.7	8.8%	1.2	EV/Sales	3.5x	48.0
In-Store and Travel	3.7	34.8%	1.3	EV/EBIT	20.0x	25.7
Hotel	1.3	34.8%	0.5	EV/EBIT	20.0x	9.3
New initiatives	4.7	-13.3%	(0.6)	EV/Sales	4.0x	18.9
Enterprise Value						101.8
(+) Net Cash						12.1
Equity Value						113.9
Diluted Shares Outstanding (mn)						6,092.6
Price Target (HK\$)						147.0

Source: CMBIS estimates



Financial Summary

Income statement					Cash flow summary						
YE 31 Dec (RMB mn)	FY18A	FY19A	FY20E	FY21E	FY22E	YE 31 Dec (RMB mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Revenue	65,227	97,529	110,112	162,567	207,567	Net income	(115,491)	2,236	(953)	10,787	18,474
Food delivery	38,143	54,323	62,589	90,423	111,925	D&A	5,367	4,846	4,403	4,164	4,936
In-store, hotel &	15,840	22,275	23,272	34,773	43,723	Change in WC	(4,987)	(3,697)	(1,736)	4,631	3,457
travel											
New initiatives	11,244	20,410	24,239	32,680	41,370	Others	105,931	2,189	2,753	3,933	4,635
COGS	(50,122)	(65,208)	(75,932)	(100,382)	(125,606)	Operating CF	(9,180)	5,574	4,467	22,073	29,556
Gross profit	15,105	32,320	34,181	62,184	81,961						
COM	(45 607)	(49.602)	(20.264)	(20 562)	(26.224)	Capex	(2,210)	(2,210)	(4,129)	(5,202)	(6,310)
S&M	(15,687)	(18,602)	(20,261)	(30,563)	(36,324)	Associates	(15,970)	(8,710)	0	0	0
Admin.Exp.	(5,168)	(3,559)	(4,184)	(5,852)	(7,099)	Others	(5,259)	746	1	(23)	(9)
R&D	(6,104)	(7,309)	(8,093)	(10,079)	(12,226)	Investing CF	(23,439)	(10,174)	(4,129)	(5,225)	(6,319)
Others	768	475	(2,681)	(3,959)	(4,802)	Facility raises d	20 516				
Operating profit	(11,086)	3,326	(1,039)	11,732	21,511	Equity raised	28,516		-	-	-
						Change of Debts	1,718	1,749	-	-	-
Financial Cost	249	(25)	85	122	223	Others	(939)	(635)	-	-	-
Fair value change	(104,606)	-	-	-	-	Financing CF	29,295	1,114	-	-	-
Others	(48)	107	-	-	-						
Pre-tax Income	(115,491)	3,408	(953)	11,853	21,734	Net change in cash	(3,323)	(3,486)	(819)	17,017	23,613
						Cash (beg of yr)	19,409	17,044	13,396	10,959	27,975
Income Tax	(2)	(526)	_	(1,067)	(3,260)	FX	1,010	(173)	(1,619)		_
Net profit	(115,493)	2,236	(953)	10,787	18,474	Cash (end of yr)	17,044	13,396	10,959	27,975	51,589
Adj. net profit	(8,517)	4,657	2,153	15,180	23,691	(, , ,					
Balance sheet						Key ratios					
YE 31 Dec (RMB mn)	FY18A	FY19A	FY20E	FY21E	FY22E	YE 31 Dec	FY18A	FY19A	FY20E	FY21E	FY22E
Non-current assets	47,512	49,878	48,661	49,870	51,398				• -		
Fixed asset	3,979	5,376	6,083	8,057	10,239	Sales mix (%) Food delivery	58.5	55.7	56.8	55.6	53.9
							24.3	22.8	21.1	21.4	21.1
Financial assets at fair value	6,242	7,166	7,166	7,166	7,166	In-store, hotel & travel	24.3	22.0	21.1	21.4	21.1
Intangible assets	33,876	32,700	31,719	30,805	30,007	New initiatives	17.2	20.9	22.0	20.1	19.9
Others	3,415	4,636	3,693	3,842	3,986	Total	100.0	99.5	100.0	97.1	94.9
Officis	3,413	4,030	3,033	3,042	3,300	lotai	100.0	33.3	100.0	37.1	34.3
Current assets	73,149	82,135	77,390	95,975	119,926	Growth rate (%)					
Cash	17,044	13,396	10,959	27,975	51,589	Revenue	92.3	49.5	12.9	47.6	27.7
Restricted cash	4,256	8,760	8,760	8,760	8,760	Gross profit	23.6	114.0	5.8	81.9	31.8
Account receivable	466	677	472 57 200	558	605	EBIT	NA NA	NA	(32.7)	679.9	65.8 56.1
Others	51,383	59,302	57,209	58,700	59,008	Net profit	INA	NA	(53.8)	605.1	30.1
Current liabilities	31,825	36,593	31,026	37,434	41,676	P&L ratios (%)					
Trade payable	5,341	6,766	6,492	10,063	13,491	Operating margin	(17.0)	3.4	(0.9)	7.2	10.4
Payable to merchants	7,596	7,495	6,252	7,384	8,013	Pre-tax margin	(177.1)	3.5	(0.9)	7.3	10.5
Advances from users	3,226	3,856	2,369	2,798	3,037	Net margin	(13.1)	4.8	2.0	9.3	11.4
Deferred revenues	3,103	4,567	2,933	3,465	3,981	Effective tax rate	(0.0)	(0.5)	-	(0.7)	(1.6)
Others	12,558	13,908	12,980	13,724	13,153	D = (==================================					
Non-current liabilities	2,327	3,366	2,502	2,595	2,608	Returns (%) ROE	(133.5)	3.7	-1.9	10.0	16.0
Borrowings	470	467	467	467	467	ROA	(8.3)	3.7	1.0	10.3	14.1
Others	-10		- -01	-	-	NOA	(0.3)	5.1	1.0	10.5	17.1
Minority interest	1,857	2,899	2,035	2,129	2,142	Per share					
•						EPS (RMB)	(3.13)	0.79	0.35	2.42	3.67
Total Equity	5	(58)	(61)	(63)	(66)	DPS (RMB)	0.00	0.00	0.00	0.00	0.00
Shareholders' equity	86,510	92,054	93,854	108,705	132,109	BVPS (RMB)	31.76	15.54	15.26	17.02	19.97

Source: Company data, CMBIS estimates



Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

Disclaimer

CMBIS or its affiliate(s) have investment banking relationship with the issuers covered in this report in preceding 12 months.

CMBIS Ratings

BUY : Stock with potential return of over 15% over next 12 months

HOLD : Stock with potential return of +15% to -10% over next 12 months

SELL : Stock with potential loss of over 10% over next 12 months

NOT RATED : Stock is not rated by CMBIS

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months

MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months

UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Securities Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Securities Limited ("CMBIS") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc...) of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

For recipients of this document in the United States

This report is intended for distribution in the United States to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this research report by its acceptance hereof represents and agrees that it shall not distribute or provide this research report to any other person.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.